Novo Nordisk expands collaboration with US app company

Shortly after the US health company Amalgam received EU approval for its app for measuring how much insulin diabetes patients need to take per day, Novo Nordisk has expanded the collaboration between the two companies.

Photo: Tidsvilde Stine/Ritzau Scanpix

Danish pharmaceutical company Novo Nordisk and US health firm Amalgam will collaborate to take over the European market for apps targeting type 2 diabetes sufferers.

Recently, the two firms agreed to expand the partnership which they commenced in 2019 over Amalgam's app, which lets patients know how much insulin they need to take over the course of the day, as fluctuations in blood sugar levels require different amounts of insulin.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs